Linde India Ltd
Linde India Limited, a subsidiary of BOC Group,UK (owns 75% stake in the co), is primarily engaged in manufacture of industrial and medical gases and construction of cryogenic and non cryogenic air separation plants.[1]
- Market Cap ₹ 54,318 Cr.
- Current Price ₹ 6,369
- High / Low ₹ 9,935 / 5,320
- Stock P/E 122
- Book Value ₹ 421
- Dividend Yield 0.06 %
- ROCE 17.4 %
- ROE 13.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 75.9% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 21.8%
Cons
- Stock is trading at 15.2 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Chemicals Industry: Chemicals
Part of Nifty LargeMidcap 250 BSE Allcap BSE Commodities BSE 150 MidCap Index BSE MidCap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2023 15m | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 1,825 | 2,033 | 2,192 | 1,762 | 1,471 | 2,112 | 3,136 | 2,769 | 2,624 | |
| 1,539 | 1,705 | 1,866 | 1,347 | 1,096 | 1,564 | 2,371 | 2,066 | 1,896 | |
| Operating Profit | 287 | 328 | 326 | 415 | 375 | 548 | 765 | 702 | 728 |
| OPM % | 16% | 16% | 15% | 24% | 25% | 26% | 24% | 25% | 28% |
| 40 | 8 | 15 | 862 | 36 | 335 | 113 | 85 | 84 | |
| Interest | 116 | 116 | 103 | 86 | 6 | 3 | 6 | 7 | 9 |
| Depreciation | 195 | 206 | 199 | 177 | 176 | 181 | 253 | 201 | 205 |
| Profit before tax | 16 | 13 | 39 | 1,013 | 229 | 698 | 618 | 579 | 597 |
| Tax % | -20% | -21% | 35% | 28% | 34% | 27% | 13% | 25% | |
| 19 | 16 | 26 | 727 | 151 | 507 | 538 | 434 | 446 | |
| EPS in Rs | 2.23 | 1.90 | 3.01 | 85.27 | 17.72 | 59.47 | 63.09 | 50.90 | 52.25 |
| Dividend Payout % | 34% | 53% | 50% | 12% | 17% | 23% | 19% | 24% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 23% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 76% |
| 3 Years: | 42% |
| TTM: | 7% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 31% |
| 5 Years: | 58% |
| 3 Years: | 38% |
| 1 Year: | 7% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 12% |
| 3 Years: | 15% |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 | 85 |
| Reserves | 1,356 | 1,365 | 1,377 | 2,087 | 2,149 | 2,630 | 3,055 | 3,383 | 3,501 |
| 1,445 | 1,282 | 1,199 | 108 | 7 | 24 | 22 | 21 | 42 | |
| 722 | 680 | 759 | 970 | 1,045 | 1,277 | 1,238 | 1,316 | 1,307 | |
| Total Liabilities | 3,608 | 3,412 | 3,420 | 3,250 | 3,286 | 4,017 | 4,400 | 4,805 | 4,936 |
| 2,573 | 2,498 | 2,162 | 2,035 | 1,989 | 1,869 | 1,762 | 1,822 | 1,817 | |
| CWIP | 80 | 36 | 44 | 53 | 17 | 68 | 225 | 483 | 791 |
| Investments | 61 | 58 | 0 | 0 | 4 | 9 | 32 | 50 | 32 |
| 895 | 821 | 1,214 | 1,162 | 1,276 | 2,071 | 2,380 | 2,450 | 2,297 | |
| Total Assets | 3,608 | 3,412 | 3,420 | 3,250 | 3,286 | 4,017 | 4,400 | 4,805 | 4,936 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|
| 293 | 252 | 376 | 327 | 339 | 589 | 629 | 437 | |
| -128 | -59 | -73 | 981 | -54 | 98 | -306 | -539 | |
| -80 | -261 | -216 | -1,193 | -201 | -28 | -119 | -105 | |
| Net Cash Flow | 85 | -68 | 87 | 115 | 84 | 659 | 203 | -208 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 71 | 63 | 61 | 79 | 101 | 73 | 47 | 63 |
| Inventory Days | 102 | 91 | 66 | 57 | 72 | 37 | 22 | 32 |
| Days Payable | 447 | 348 | 293 | 327 | 477 | 312 | 156 | 235 |
| Cash Conversion Cycle | -274 | -194 | -166 | -190 | -303 | -202 | -87 | -139 |
| Working Capital Days | -50 | -42 | -33 | -24 | 13 | -3 | -9 | -11 |
| ROCE % | 5% | 5% | 10% | 10% | 17% | 21% | 17% |
Documents
Announcements
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 15 Nov
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
9 Nov - Letter no. Sect/121 dated 9 November 2024 attaching pdf copies of newspaper publications containing extract of Consolidated Financial Results of the Company for the quarter …
- Updates On Outcome Of Board Meeting Held On 7 November 2024 7 Nov
-
Board Meeting Outcome for Updates On Outcome Of Board Meeting Held On 7 November 2024
7 Nov - Board approved unaudited financial results for Q2 2024.
-
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
6 Nov - Intimation of loss of share certificates and request for duplicates.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from nse
-
Financial Year 2010
from bse
Business Segment
Gas and Related Products: It comprises of pipeline gas supplies to large industrial customers like primary steel, glass and chemical industries, supply of liquefied gases through Cryogenic tankers (Bulk) to cater to demand across a wide range of industrial sectors and compressed gas supply in cylinders (Packaged Gas) for meeting smaller demand for gases mainly across fabrication, manufacturing and construction industry.
Healthcare business: It provides high quality gases for pharmaceutical use such as medical oxygen, synthetic air and nitrous oxide in addition to providing state of the art medical gas distribution systems to major hospitals.
Project Engineering division (PED): It comprises the business of design, engineering, supply, installation, testing and commissioning of Air Separation plants and related projects on turnkey basis. [1][2]